- Previous Close
19.07 - Open
25.75 - Bid 29.19 x 200
- Ask 29.54 x 100
- Day's Range
24.84 - 29.95 - 52 Week Range
5.12 - 29.95 - Volume
11,808,291 - Avg. Volume
974,509 - Market Cap (intraday)
2.766B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-1.53 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.60
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
www.edgewisetx.comRecent News: EWTX
View More
Performance Overview: EWTX
Trailing total returns as of 9/19/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EWTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EWTX
View MoreValuation Measures
Market Cap
1.79B
Enterprise Value
1.28B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.74%
Return on Equity (ttm)
-28.20%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-115.88M
Diluted EPS (ttm)
-1.53
Balance Sheet and Cash Flow
Total Cash (mrq)
511.75M
Total Debt/Equity (mrq)
0.98%
Levered Free Cash Flow (ttm)
-62.31M
Research Analysis: EWTX
View MoreCompany Insights: EWTX
EWTX does not have Company Insights
Research Reports: EWTX
View MoreDaily – Vickers Top Buyers & Sellers for 12/29/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/19/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/28/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.